What are the challenges associated with CAR T-cell therapy in patients with AML?
During the 6th European CAR T-Cell Meeting, the AML Hub spoke to Sarah Tettamanti, Tettamanti Foundation Research Center, Monza, IT. We asked, What are the challenges associated with CAR T-cell therap...
25 Huhti 20249min
How might the MORPHO trial of gilteritinib impact clinical practice?
The AML Hub spoke to Charles Craddock, Queen Elizabeth Hospital Birmingham, Birmingham, UK at ASH 2023. We asked, How might the MORPHO trial of gilteritinib impact clinical practice? Hosted on Acast. ...
8 Huhti 20247min
Risk stratification and guidelines in AML management
The AML Hub was pleased to speak to Gail Roboz, Weill Cornell Medicine, New York, US, and Naval Daver, MD Anderson Cancer Center, Houston, US. We asked about risk stratification and guidelines in acut...
8 Tammi 202411min
How are new fludarabine conditioning combinations impacting transplant outcomes?
During the virtual 48th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), the AML Hub spoke with Eleni Gavriilaki, George Papanikolaou General Hospital of Thessalonik...
22 Huhti 20226min
Should pre-transplant MRD be used to guide treatment in AML?
During the EHA2021 Virtual Congress, the AML Hub spoke with Arnon Nagler, Tel Aviv University, Tel Aviv, IL. We asked, Should pre-transplant measurable residual disease (MRD) be used to guide treatmen...
10 Heinä 20216min
Should pre-transplant MRD be used to guide treatment in AML?
During the EHA2021 Virtual Congress, the AML Hub spoke with Charles Craddock, Queen Elizabeth Hospital Birmingham, Birmingham, UK. We asked, Should pre-transplant minimal residual disease (MRD) be use...
25 Kesä 202113min
Should pre-transplant MRD be used to guide treatment in AML?
During the EHA2021 Virtual Congress, the AML Hub spoke with Gert Ossenkoppele, Amsterdam UMC, Amsterdam, NL. We asked, Should pre-transplant minimal residual disease (MRD) be used to guide treatment i...
23 Kesä 20215min
Can HMA maintenance therapy improve eligibility for HSCT?
During the 2021 TCT Meetings Digital Experience, the AML Hub spoke to Farhad Ravandi, MD Anderson Cancer Center, Houston, US. We asked, Can HMA maintenance therapy improve eligibility for HSCT? Ravand...
17 Maalis 20215min
